文献速递血栓与止血

炎症性肠病合并静脉血栓栓塞患者口服抗凝药的出血与血栓结局

Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism.
PubMed 文献 · Blood Adv · 2026-01-01

研究比较炎症性肠病(IBD)合并静脉血栓栓塞(VTE)患者使用直接口服抗凝药(DOAC)与华法林的复发性VTE及出血风险。倾向评分匹配后纳入2174例(DOAC组1087例,华法林组1087例),DOAC组出血风险较低(HR 0.59,95%CI 0.41-0.85),复发性VTE无差异(HR 0.82,95%CI 0.59-1.15)。次要分析显示接受DOAC的IBD患者出血风险约为无IBD者的两倍(HR 1.99,95%CI 1.64-2.41)。

要点

  • IBD合并VTE患者中,DOAC较华法林出血风险更低(HR 0.59,95%CI 0.41-0.85)。
  • DOAC与华法林相比复发性VTE风险无显著差异(HR 0.82,95%CI 0.59-1.15)。
  • 接受DOAC的IBD患者出血风险约为无IBD者的两倍(HR 1.99,95%CI 1.64-2.41)。

核心结论

  • IBD合并VTE患者中,DOAC使用与较华法林更低的出血风险相关,复发性VTE风险无显著差异。
  • 即使使用DOAC,IBD患者发生严重出血的可能性约为无IBD者的两倍,凸显密切监测的重要性。

研究设计与样本

  • 研究纳入新处方DOAC或华法林的成人IBD合并VTE患者,采用倾向评分匹配后Cox比例风险模型估计HR及95%CI。
  • 匹配后的IBD口服抗凝药队列共2174例,其中DOAC使用者1087例、华法林使用者1087例。
  • 次要分析比较接受DOAC的IBD患者与无IBD患者的出血风险。

主要发现

  • 倾向评分匹配后,DOAC组较华法林组出血风险更低(HR 0.59,95%CI 0.41-0.85)。
  • DOAC组与华法林组复发性VTE风险无显著差异(HR 0.82,95%CI 0.59-1.15)。
  • 次要分析中,接受DOAC的IBD患者较无IBD患者出血风险升高约两倍(HR 1.99,95%CI 1.64-2.41)。

临床怎么用

  • 原文结论指出,即使使用DOAC,IBD患者严重出血风险仍约为无IBD者的两倍,强调密切监测的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with inflammatory bowel disease (IBD) are at an increased risk of venous thromboembolism (VTE) and bleeding. We aimed to compare the risk of recurrent VTE and bleeding between direct oral anticoagulants (DOACs) and warfarin in patients with IBD and VTE. The study included adults with IBD and VTE who were newly prescribed DOACs or warfarin. The primary study outcomes were recurrent VTE and a composite of serious bleeding. We used Cox proportional hazard model after propensity score matching to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). In a secondary analysis, we compared the risk of bleeding in patients on DOACs with IBD vs patients without IBD. Our matched IBD cohort of patients initiating oral anticoagulants comprised 2174 patients (1087 DOAC users and 1087 warfarin users). After propensity score matching, DOAC use (compared with warfarin) was associated with a lower risk of bleeding (HR, 0.59; 95% CI, 0.41-0.85) with no difference in the risk of recurrent VTE (HR, 0.82; 95% CI, 0.59-1.15). In the secondary analysis of patients with VTE who received DOACs, there was a twofold increase in the risk of bleeding in patients with IBD compared with those without IBD (HR, 1.99; 95% CI, 1.64-2.41). In patients with IBD and VTE, DOAC use was associated with a lower risk of bleeding compared with warfarin, without a significant difference in the risk of recurrent VTE. However, even with the use of DOACs, patients with IBD were twice as likely to experience serious bleeding as those without IBD, highlighting the importance of close monitoring.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dawwas GK, Cuker A, Lewis JD, et al. Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism. Blood Adv. 2026. PMID: 41191527. doi:10.1182/bloodadvances.2025017617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。